requesting information regarding atrial fibrillation in NHS West Kent Clinical Commissioning Group
|
|
- Samuel Charles Green
- 5 years ago
- Views:
Transcription
1 NHS Wet Kent Clinical Commiioning Group October 2015 Our Ref: FOI.15.WK0138 requeting information regarding atrial fibrillation in NHS Wet Kent Clinical Commiioning Group Pleae find attached a Freedom of Information requet on the ubject of atrial fibrillation. Pleae find attached: 1) Your completed urvey, alo hown a Appendix A at the end of thi letter 2) Primary care atrial fibrillation pathway A COPY OF THE PRIMARY CARE ATRIAL FIBRILLATION PATHWAY IS AVAILABLE UPON REQUEST
2 Appendix A Atrial Fibrillation in Your Area Quetion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What wa the prevalence of atrial fibrillation (AF)? I can confirm NHS Wet Kent Clinical Commiioning Group (CCG) may hold thi information. However, NHS Wet Kent CCG conider thi information i exempt under ection 21 of the Act a the information i reaonably acceible to the Applicant by another route. The information i publihed within the Public Health Obervatory webite, available on the following link: b) How many patient were diagnoed with AF? During the period requeted, 59 patient were referred to the Primary Care Cardiology ervice. However, patient can alo be diagnoed within econdary care to acce thi information you may wih to contact NHS Wet Kent CCG main acute provider, Maidtone and Tunbridge Well NHS Trut (MTW). They can be contacted at: MTW-TR.FOIadmin@nh.net c) How many patient received a manual pule check for AF? GP are encouraged to undertake opportunitic teting on patient a they preent. Some practice carry out thee check during flu clinic, for example. However, NHS Wet Kent CCG doe not hold exact number a it would be difficult to quantify. Quetion 2: Which of the criteria lited below i included in the peronalied package of care offered to patient with AF? (Pleae tick the boxe that apply) I can confirm that NHS Wet Kent CCG doe not hold thi information. All patient care i individualied, however ome may be managed by the GP and Practice Nure, and other will be referred on to an acute trut for management by a cardiologit. NHS Wet Kent Clinical Commiioning Group
3 Peronalied Package of Care and Information NICE Clinical Guideline 180 Atrial Fibrillation: the management of atrial fibrillation make the following recommendation on offering patient with AF a peronalied package of care: Offer people with atrial fibrillation a peronalied package of care. Enure that the package of care i documented and delivered, and that it cover: - AF-related troke awarene and meaure to prevent AF-related troke - rate control - aement of ymptom for rhythm control - who to contact for advice if needed - pychological upport if needed - up-to-date and comprehenive education and information on: caue, effect and poible complication of atrial fibrillation management of rate and rhythm control anticoagulation; practical advice on anticoagulation in line with recommendation in 'Venou thromboembolic dieae' (NICE clinical guideline 144) upport network (for example, cardiovacular charitie). Quetion 3: What tep doe your CCG take to verify that patient with AF are being offered a peronalied package of care? I can confirm that NHS Wet Kent CCG doe not currently have any proce in place to verify that patient with AF are being offered a peronalied package of care. However, in September 2015 the CCG implemented a Local Incentive Scheme for practice which focue on increaing anticoagulation in patient diagnoed with AF. The overall ambition i to increae the rate of anticoagulation, reducing the number of troke econdary to AF. Quetion 4: What upport network and information are advertied and provided to patient with AF? I can confirm that NHS Wet Kent CCG doe not currently have any proce in place with regard to upport network or information provided to patient with AF. However, the topic of AF i frequently included on the agenda at GP education event and we are alo undertaking an audit of AF from the GRASP-AF Local Incentive Scheme (a mentioned above). NHS Wet Kent Clinical Commiioning Group
4 Quetion 5: Between 1 July 2014 and 30 June 2015, how many patient in the area covered by your CCG have been referred for pecialied management due to: a.) Failure of AF treatment to control the ymptom of AF? b.) Recurrence of AF following cardioverion? NHS Wet Kent CCG doe not hold thi information. Maidtone and Tunbridge Well NHS Trut (MTW) provide thi ervice o you may wih to redirect your requet to MTW, who can be contacted on the following detail: MTW-TR.FOIadmin@nh.net Pleae alo be aware that patient within the NHS Wet Kent CCG area may alo be treated in London hopital by other provider. Referral for Specialied Management NICE Clinical Guideline 180 make the following recommendation regarding referral for pecialied management: Refer people promptly at any tage if treatment fail to control the ymptom of atrial fibrillation and more pecialied management i needed. Quetion 6: What tep do your provider take to enure that people with any of the above condition are aeed for AF-related troke rik uing the CHA2DS2-VASc troke rik core? A part of the GP Local Incentive Scheme, practice within NHS Wet Kent CCG are running the GRASP-AF audit tool to detect patient (with AF) with a CHA2DS2-VASc core of >1 and are not anticoagulated. Aement of Stroke and Bleeding Rik NICE Clinical Guideline 180 make the following recommendation regarding aement of AF- related troke rik: AF- Related Stroke rik Ue the CHA2DS2-VASc troke rik core to ae AF-related troke rik in people with any of the following: - ymptomatic or aymptomatic paroxymal, peritent or permanent atrial fibrillation - atrial flutter a continuing rik of arrhythmia recurrence after cardioverion back to inu rhythm. Quetion 7: What tep do your provider take to enure that the HAS-BLED core i ued to ae the rik of bleeding in people who are tarting or have tarted anticoagulation? The ue of the HAS-BLED core i included in the NHS Wet Kent CCG Primary Care Atrial Fibrillation Pathway (ee attached). NHS Wet Kent Clinical Commiioning Group
5 NICE Clinical Guideline 180 make the following recommendation regarding aement of bleeding rik: Bleeding rik Ue the HAS-BLED core to ae the rik of bleeding in people who are tarting or have tarted anticoagulation. Offer modification and monitoring of the following rik factor: - uncontrolled hypertenion - poor control of international normalied ratio (INR) ('labile INR') - concurrent medication, for example concomitant ue of apirin or a non-teroidal anti-inflammatory drug (NSAID) - harmful alcohol conumption. Quetion 8: Of the patient who were treated for AF in the area covered by your CCG between 1 July 2014 and 30 June 2015, how many had a CHA2DS2-VASc core of 2 or above? NHS Wet Kent CCG doe not hold thi information. Intervention to prevent troke NICE Clinical Guideline 180 make the following recommendation regarding intervention to prevent AF-related troke: Anticoagulation Anticoagulation may be with apixaban, dabigatran etexilate, rivaroxaban, edoxaban or a vitamin K antagonit. Offer anticoagulation to people with a CHA2DS2-VASc core of 2 or above, taking bleeding rik into account. Quetion 9: Of thee patient, how many were treated for AF-related troke prevention with: a.) Anticoagulation therapy (therapy which reduce the body ability to form clot in the blood)? NHS Wet Kent CCG doe not hold thi information. b.) Apirin monotherapy (the treatment of AF with apirin alone)? NHS Wet Kent CCG doe not hold thi information. However, the CCG doe not recommend apirin monotherapy, although the treatment of all patient i individualied to their need. NHS Wet Kent Clinical Commiioning Group
6 Quetion 10: What guidance do you give to your provider to enure they are precribing an appropriate anticoagulant approved by NICE for AF-related troke prevention rather than apirin monotherapy? I can confirm NHS Wet Kent CCG doe hold the information you requeted. The CCG conider that thi information i exempt under ection 21 of the Act a the information i reaonably acceible to the Applicant by another route. The information i publihed within a joint webite by NHS Wet Kent CCG and MTW, and can be found under Therapeutic Section > 2. Cardiovacular Sytem > Oral anticoagulant. The information you requeted i alo available on the following link: Quetion 11: Of the patient treated with anticoagulation therapy for AF-related troke prevention in the area covered by your CCG between 1 July 2014 and 30 June 2015, what percentage were treated with: a.) A novel oral anticoagulant (NOAC)? b.) Warfarin? NICE Clinical Guideline 180 make the following recommendation regarding ue of antiplatelet: Antiplatelet Do not offer apirin monotherapy olely for troke prevention to people with atrial fibrillation. I can confirm NHS Wet Kent CCG doe not hold thi information. NHS Wet Kent CCG hold information on medication unit precribed but patient diagnoi i recorded within individual health record; therefore they would be unable to etablih if a pecific medication ha been precribed to treat a pecific condition. Information on precribing data i available in the public domain; you may wih to try earching within the NHS Buine Service Authority (NHSBSA) Information Service Portal, via the Guet Login. Once on the webpage you can acce the information by clicking on the +Data icon at the top left ide of the webpage, next chooing the Precribing Data option and finally chooing the Detailed Precribing Information option. Another option would be to acce the Health and Social Care Information Centre (HSCIC) on the following link: Search?q=gp+practice+precribing+preentation&go=Go&area=both A the GP practice may hold the information you have requeted in thi quetion; you may wih to redirect thi part of your requet to them. A lit of all NHS Wet Kent CCG GP practice can be found on their webite, acceible on the following link: NHS Wet Kent Clinical Commiioning Group
7 Quetion 12: Do your provider offer rate-control a the firt-line trategy to patient with AF? *AF i aociated with an increaed heart rate, which can caue both immediate and long term health conequence. Rate control ue drug approved by NICE or urgical intervention to reduce the ventricular heart rate, and thereby improve ymptom and reduce the rik of aociated morbidity. Rate and rhythm control NICE Clinical Guideline 180 make the following recommendation regarding rate and rhythm control: Offer rate control* a the firt-line trategy to people with atrial fibrillation, except in people: - whoe atrial fibrillation ha a reverible caue - who have heart failure thought to be primarily caued by atrial fibrillation - with new-onet atrial fibrillation - with atrial flutter whoe condition i conidered uitable for an ablation trategy to retore inu rhythm for whom a rhythm control trategy would be more uitable baed on clinical judgement. NHS Wet Kent CCG ue the attached pathway which give guidance to clinician on which approach to take, rate or rhythm control. A per the protocol mot patient will fall under the rate control approach. NHS Wet Kent Clinical Commiioning Group
requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationCommissioning for Value Where to Look pack
Commiioning for Value Where to Look pack Surrey Heartland - STP area December 2016 Neurological April 2016 Content Introduction to your Where to Look pack Supporting the STP proce NHS RightCare and Getting
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More informationCommissioning for Value Where to Look pack
Commiioning for Value Where to Look pack South Eat London - STP area December 2016 Neurological April 2016 Content Introduction to your Where to Look pack Supporting the STP proce NHS RightCare and Getting
More informationCommissioning for Value Where to Look pack
Commiioning for Value Where to Look pack North Eat London - STP area December 2016 Neurological April 2016 Content Introduction to your Where to Look pack Supporting the STP proce NHS RightCare and Getting
More information- how many anti-depressant pills were prescribed to patients in years 2011/12/13
NHS Wet Kent Clinical Commiioning Group Our Ref: FOI.14.WK0196 RE: FREEDOM OF INFORMATION REQUEST Thank you for your requet for information under the Freedom of Information Act 2000 received on 25 February
More informationRhona Maclean
An early evaluation of the impact of the North Trent policy regarding the use of Non-Vitamin K antagonists for SPAF in a secondary care anticoagulation clinic Rhona Maclean Rhona.maclean@sth.nhs.uk Risk
More informationCommissioning for Value Where to Look pack
Commiioning for Value Where to Look pack Frimley Health - STP area December 2016 Neurological April 2016 Content Introduction to your Where to Look pack Supporting the STP proce NHS RightCare and Getting
More informationINFORMATION EXTRACTED FROM CDMP HANDBOOK ON DEMENTIA
dementia INFORMATION EXTRACTED FROM CDMP HANDBOOK ON DEMENTIA _ CHRONIC DISEASE MANAGEMENT PROGRAMME for dementia INTRODUCTION The following page are elected from the Handbook for Healthcare Profeional
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationAppendix A: Clinical question and search strategies
APPENDICES Appendix A: Clinical quetion and earch trategie Study type Quetion ID Quetion wording filter ued Databae and year PHAR2a What i the afety and efficacy of apirin veru Sytematic review, Medline
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationAgenda Item No. 8a SERVICE SPECIFICATION. 1. Introduction:
SERVICE SPECIFICATION Agenda Item No. 8a Service Specification No. Service Atrial Fibrillation Audit patient reviews Commissioner Lead Caroline Davidson Period 1 st September to 31 st March 2017 Date of
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationNHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation
1 NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation Atrial fibrillation (AF) affects about 1.2% of the population in the United Kingdom and accounts
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationDr Mammen Ninan GPwSI in Cardiology
Dr Mammen Ninan GPwSI in Cardiology AF affects up to 835,000 people in England alone and is expected to rise year after year. AF is a known risk factor for stroke, the 3 rd highest cause of mortality in
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More informationThat the Single Commissioning Board supports the project outlined in this report and proceeds as described.
Report to: SINGLE COMMISSIONING BOARD Date: 26 September 2017 Officer of Single Commissioning Board Subject: Report Summary: Recommendations: Jessica Williams Interim Director of Commissioning ATRIAL FIBRILLATION
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationAF Diagnosis. Incorporated into over 75 health checks and Public Health Checks
AF Diagnosis Incpated into over 75 health checks and Public Health Checks Pulse Feel the pulse in all >65yrs If irregular do a 12 Lead ECG with Rhythm strip Check Thyroid and FBC and heart rate Refer to
More informationANAEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE
The National Collaborating Centre for Chronic Condition Funded to produce guideline for the NHS by NICE ANAEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE National clinical guideline for management in adult
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationAlison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationMULTIPLE SCLEROSIS. National clinical guideline for diagnosis and management in primary and secondary care
The National Collaborating Centre for Chronic Condition Funded to produce guideline for the NHS by NICE MULTIPLE SCLEROSIS National clinical guideline for diagnoi and management in primary and econdary
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationAtrial Fibrillation. CVD Clinical Development Coordinator
Atrial Fibrillation CVD Clinical Development Coordinator Atrial Fibrillation What it is and why it's important Case identification Heart rate control and onward referral Managing AF-Related Stroke risk
More informationAHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017
AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke Version: 13 March 2017 Introduction This business case template has been created so that
More informationPrimary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More information18/09/2012. Dr. Khalid Khan Consultant Cardiologist BCUHB. Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham
Dr. Khalid Khan Consultant Cardiologist BCUHB Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham 1 NICE vs. Local Guidance NICE says no We say no NICE says yes We say no NOACs
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationAF Treatment & Anticoagulation
AF Treatment & Anticoagulation Dr Matthew Lovell, mattlovell@exeterheart.com Consultant Cardiologist & Electrophysiologist! Exeter Heart & Royal Devon and Exeter Hospital NICE Guidance NICE Guidance for
More informationCITALOPRAM - 20 Pr. CITALOPRAM - 40 Citalopram Tablets, USP PART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr CITALOPRAM - 20 Pr CITALOPRAM - 40 Citalopram Tablet, USP Thi leaflet i part III of a three-part "Product Monograph" publihed when CITALOPRAM wa approved for ale in Canada
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationTricky Cases in Primary Care Anticoagulation in AF
Tricky Cases in Primary Care Anticoagulation in AF Dr John Wong GPwSI Cardiology & GP Principal Leatherhead Hospital Ashlea Medical Practice 54 year old F Case 1 PMH CREST Syndrome calcinosis finger tips
More informationAtrial fibrillation and anticoagulation therapy
Atrial fibrillation and anticoagulation therapy This leaflet offers more information about atrial fibrillation for patients who have been advised that they need anticoagulation therapy. If you have any
More informationManagement of non-valvular Atrial Fibrillation
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of non-valvular Atrial Fibrillation Guidelines for anticoagulation apply to paroxysmal, persistent and permanent AF and atrial flutter. Do
More informationTackling atrial fibrillation the health economics evidence
Tackling atrial fibrillation the health economics evidence Professor Gary Ford,CBE Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals
More informationEXPLORING COGNITIVE STRATEGIES FOR INTEGRATING MULTIPLE-VIEW VISUALIZATIONS
EXPLORING COGNITIVE STRATEGIES FOR INTEGRATING MULTIPLE-VIEW VISUALIZATIONS Young Sam Ryu 1, Beth Yot 2, Gregorio Convertino 2, Jian Chen 2, and Chri North 2 Grado Department of Indutrial and Sytem Engineering
More informationIMPORTANT: PLEASE READ currently taking or have recently taken thioridazine or pimozide.
PART III: CONSUMER INFORMATION Pr PAROXETINE Paroxetine (a Paroxetine Hydrochloride) Tablet Manufacturer Standard IMPORTANT: PLEASE READ currently taking or have recently taken thioridazine or pimozide.
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationby Pace et al. (1985). These investigators developed
JOURNAL OF APPLIED BEHAVIOR ANALYSIS 19921 259 491-498 NUMBEP. 2 (ummep. 1992) A COMPARISON OF TWO APPROACHES FOR IDENTIFYING REINFORCERS FOR PERSONS WITH SEVERE AND PROFOUND DISABILITIES WAYNE FiHm, CAmLEEN
More informationProvide Pain Management theory answer paper Multiple choice
Provide Pain Management theory anwer paper Multiple choice You will need to complete a theory paper coniting of four (4) ection with both multiple choice and hort anwer quetion. Section 1 and 2 are compulory.
More informationOptimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationAppendix Am A Comparison of the National Cancer Institute s and the International Agency for Research on Cancer s Evaluation of Bioassay Results
Appendixe.. Content Page Appendix A: A Comparion of the National Cancer ntitute and the nternational Agency for Reearch on Cancer Evaluation of Bioaay Reult...........................................211
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationAtrial Fibrillation and Anticoagulants
Atrial Fibrillation and Anticoagulants A guide to your diagnosis and treatment Information for patients, relatives and carers For more information, please contact: York Anticoagulant Clinic Tel: 01904
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationInitial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care
Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care 11 th and 25 th September 2014 3 KEY OBJECTIVES OF TALK 1.
More informationOptimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationCHRONIC KIDNEY DISEASE
The National Collaborating Centre for Chronic Condition Funded to produce guideline for the NHS by NICE CHRONIC KIDNEY DISEASE National clinical guideline for early identification and management in adult
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationAn FSIS Update on the Prevention and Control of Foodborne Salmonella
1 Outline An FSIS Update on the Prevention and Control of Foodborne Salmonella Karen Becker, DVM, MPH, DACVPM Director, Applied USDA/ USAHA Salmonella Committee Providence, RI Oct 27, 2015 2 FSIS Miion
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationA DECISION AID FOR AFIB STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION
A DECISION AID FOR AFIB STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION For Patients with HIGH RISK You have atrial fibrillation, also known as AFib, which means you have an irregular heart beat.
More informationManagement of non-valvular Atrial Fibrillation
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of non-valvular Atrial Fibrillation Guidelines for anticoagulation apply to paroxysmal, persistent and permanent AF and atrial flutter. Do
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationUpdates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
More informationKarnofsky Performance Scale (KPS) or Physical Performance Test (PPT)? That is the question
Critical Review in Oncology/Hematology 77 (2011) 142 147 Karnofky Performance Scale (KPS) or Phyical Performance Tet (PPT)? That i the quetion Catherine Terret a,b,c,, Gille Albrand b,c,d, Géraldine Moncenix
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial Response
More informationThe first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
More informationSAMPLE. Relative Values for Physicians. Relative values based on physician survey data from Relative Value Studies, Inc. ICD-10.
www.optumcoding.com Relative Value for Phyician Relative value baed on phyician urvey data from Relative Value tudie, Inc. AMPLE 2017 a ICD-10 A full uite of reource including the latet code et, mapping
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationAudit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy
Save A Stroke Campaign 2016 Quality Improvement Cardiff & Vale UHB & Public Health Wales Audit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy 1 Quality Improvement [AUDIT+
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationManagement of non-valvular Atrial Fibrillation
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of non-valvular Atrial Fibrillation Guidelines for anticoagulation apply to paroxysmal, persistent and permanent AF and atrial flutter. Do
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationTo Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin
To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin Omprakash Pansara, MD Brian Kline, MD St. Joseph s Health Family Medicine Residency Program, Syracuse, NY Case 75yr old male, who
More informationFeedback from the EMA
Feedback from the EMA Jens Heisterberg, MD Danish Medicines Agency Is There a Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? CSRC Meeting, Washington D.C., December 3,
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More information